Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations

Bibliography

• PISANI P, PARKIN DM, BRAY F, FERLAY J: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer (1999) 83:18-29.
   PubMed Web of Science ®Google Scholar
• PAGE N, READ W, TIERNEY R, ARQUETTE M, PICCIRILLO J, GOVINDAN R: The epidemiology of small cell lung canrcinoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:305 (Abstract 1216).
   Google Scholar
• STUPP R, MONNERAT C, TURRISI AT, 3rd, PERRY MC, LEYVRAZ S: Small cell lung cancer: state of the art and future perspectives. Lung Cancer (2004) 45(1):105-117.
   PubMed Web of Science ®Google Scholar
• COMIS RL, FRIEDLAND DM, GOOD BC: Small-cell lung cancer: a perspective on the past and a preview of the future. Oncology (1998) 12(1 Suppl 2):44-50.
   PubMedGoogle Scholar
• WOLF M, TEBBE S, FINK T: First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer (2004) 45(Suppl. 2):S223-S234.
   PubMed Web of Science ®Google Scholar
• IYER L, KING CD, WHITINGTON PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. (1998) 101(4):847-854.
   PubMed Web of Science ®Google Scholar
• MCLEOD HL: Drug pathways: moving beyond single gene pharmacogenetics. Pharmacogenomics (2004) 5(2):139-141.
   PubMed Web of Science ®Google Scholar
• SPARREBOOM A, DANESI R, ANDO Y, CHAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Updat. (2003) 6(2):71-84.
   PubMed Web of Science ®Google Scholar
• MARSH S, MCLEOD HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics (2004) 5(7):835-843.
   PubMed Web of Science ®Google Scholar
• MA MK, MCLEOD HL: Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. (2003) 10(1):41-49.
   PubMed Web of Science ®Google Scholar
• DE JONG FA, DE JONGE MJ, VERWEIJ J, MATHIJSSEN RH: Role of pharmacogenetics in irinotecan therapy. Cancer Lett. (2005) Epub ahead of print.
   PubMedGoogle Scholar
• TAKIMOTO CH: Chapter 15: Pharmacology of Cancer Chemotherapy: Section 7: Topoisomerase Interactive Agents. 7th Ed., Philadelphia: Lippincott Williams & Wilkins (2005):375-390.
   Google Scholar
• KUHN JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (2002) 16(8 Suppl. 7):33-40.
   PubMedGoogle Scholar
• YONEMORI K, TAKEDA Y, TOYOTA E, KOBAYASHI N, KUDO K: Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer. Int. J. Clin. Oncol. (2004) 9(3):206-209.
   PubMedGoogle Scholar
• MATHIJSSEN RH, VERWEIJ J, DE BRUIJN P, LOOS WJ, SPARREBOOM A: Effects of St. John's wort on irinotecan metabolism. J. Natl. Cancer Inst. (2002) 94(16):1247-1249.
   PubMed Web of Science ®Google Scholar
• KEHRER DF, MATHIJSSEN RH, VERWEIJ J, DE BRUIJN P, SPARREBOOM A: Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. (2002) 20(14):3122-3129.
   PubMed Web of Science ®Google Scholar
• OHE Y: Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med. (2002) 44(3):205-212.
   PubMed Web of Science ®Google Scholar
• ABIGERGES D, ARMAND JP, CHABOT GG et al.: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer. Inst. (1994) 86(6):446-449.
   PubMed Web of Science ®Google Scholar
• ARMAND JP, TERRET C, COUTEAU C, RIXE O: CPT-11. The European experience. Ann. N Y Acad. Sci. (1996) 803:282-291.
   PubMed Web of Science ®Google Scholar
• KUDOH S, FUJIWARA Y, TAKADA Y et al.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol. (1998) 16(3):1068-1074.
   PubMed Web of Science ®Google Scholar
• KUBOTA K, NISHIWAKI Y, SUGIURA T et al.: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin. Cancer Res. (2005) 11(15):5534-5538.
   PubMed Web of Science ®Google Scholar
• VON PAWEL J, SCHILLER JH, SHEPHERD FA et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. (1999) 17(2):658-667.
   PubMed Web of Science ®Google Scholar
• VON PAWEL J: The role of topotecan in treating small cell lung cancer: second-line treatment. Lung Cancer (2003) 41(Suppl. 4):S3-S8.
   PubMed Web of Science ®Google Scholar
• NEGORO S, FUKUOKA M, NIITANI H, TAGUCHI T: Phase II study of CPT-11, new camptothecin derivative, in small cell lng cancer (SCLC) (abstract). Proc. Am. Soc. Clin. Oncol. (1991) 10:214.
   Google Scholar
• MASUDA N, FUKUOKA M, KUSUNOKI Y et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1992) 10(8):1225-1229.
   PubMed Web of Science ®Google Scholar
• NODA K, NISHIWAKI Y, KAWAHARA M et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. (2002) 346(2):85-91.
   PubMed Web of Science ®Google Scholar
• HANNA NH, EINHORN L, SANDLER A et al.: Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. (2005) 23:622s.
   Google Scholar
• TAKIGAWA N, FUJIWARA K, UEOKA H et al.: Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study. Anticancer Res. (2003) 23(1B):557-560.
   PubMed Web of Science ®Google Scholar
• HAN JY, LEE DH, LEE SY et al.: A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer. Med. Oncol. (2005) 22(3):281-290.
   PubMed Web of Science ®Google Scholar
• SCHMITTEL A, SCHULZE K, HUTTER G, KREBS P, THIEL E, KEILHOLZ U: Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie (2004) 27(3):280-284.
   PubMed Web of Science ®Google Scholar
• FUKUDA M, OKA M, SODA H et al.: Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin. Cancer Res. (1999) 5(12):3963-3969.
   PubMed Web of Science ®Google Scholar
• SCHMITTEL A, FISCHER VON WEIKERSTHAL L, SEBASTIAN M et al.: Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: A randomized phase II trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:632s.
   Google Scholar
• KUDOH S, NAKAMURA S, NAKANO T et al.: Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. Lung Cancer (2005) 49(2):263-269.
   PubMed Web of Science ®Google Scholar
• SEKINE I, NISHIWAKI Y, NODA K et al.: Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann. Oncol. (2003) 14(5):709-714.
   PubMed Web of Science ®Google Scholar
• BRIASOULIS E, SAMANTAS E, KALOFONOS H et al.: Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. Cancer Chemother. Pharmacol. (2005) 56(5):521-528.
   PubMed Web of Science ®Google Scholar
• SAMANTAS E, SYRIGOS K, BRIASOULIS E et al.: Phase II study of cisplatin plus etoposide over 3 days combined with irinotoecan and early thoracic radiotherapy (TRT) in patients with limited disease (LD) small cell lung cancer (SCLC), preliminary results. Lung Cancer (2005) 49(Suppl. 2):S327.
   Web of Science ®Google Scholar
• THOMPSON DS, HAINSWORTH JD, SPIGEL DR et al.: Irinotecan (I), carboplatin (C), and imatinib (IM) in the first-line treatment of extensive-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2005) 23:632s.
   Google Scholar
• HUISMAN C, POSTMUS PE, GIACCONE G, SMIT EF: Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat. Rev. (1999) 25(4):199-206.
   PubMed Web of Science ®Google Scholar
• ANDO M, KOBAYASHI K, YOSHIMURA A et al.: Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer (2004) 44(1):121-127.
   PubMed Web of Science ®Google Scholar
• NAKA N, KAWAHARA M, OKISHIO K et al.: Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer (2002) 37(3):319-323.
   PubMed Web of Science ®Google Scholar
• HIROSE T, HORICHI N, OHMORI T et al.: Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer (2003) 40(3):333-338.
   PubMed Web of Science ®Google Scholar
• MASUDA N, MATSUI K, NEGORO S et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J. Clin. Oncol. (1998) 16(10):3329-3334.
   PubMed Web of Science ®Google Scholar
• AGELAKI S, SYRIGOS K, CHRISTOPHYLAKIS C et al.: A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology (2004) 66(3):192-196.
   PubMed Web of Science ®Google Scholar
• SCHUETTE W, NAGEL S, JUERGENS S et al.: Phase II trial of gemcitabine/Irinotecan in refractory or relapsed small-cell lung cancer. Clin. Lung Cancer (2005) 7(2):133-137.
   PubMed Web of Science ®Google Scholar
• ICHIKI M, GOHARA R, RIKIMARU T et al.: Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy (2003) 49(4):200-205.
   PubMed Web of Science ®Google Scholar
• RUSHING DA: Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC. Oncology (Huntingt) (2000) 14(7 Suppl. 5):63-66.
   PubMed Web of Science ®Google Scholar
• SEKINE I, NISHIWAKI Y, KAKINUMA R et al.: Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. Br. J. Cancer (2003) 88(6):808-813.
   PubMed Web of Science ®Google Scholar
• GOTO K, SEKINE I, NISHIWAKI Y et al.: Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br. J. Cancer (2004) 91(4):659-665.
   PubMed Web of Science ®Google Scholar
• FUJITA A, TAKABATAKE H, TAGAKI S, SEKINE K: Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer. Oncology (2000) 59(2):105-109.
   PubMed Web of Science ®Google Scholar
• PIGNON JP, ARRIAGADA R, IHDE D et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. (1992) 327:1618-1624.
   PubMed Web of Science ®Google Scholar
• WARDE P, PAYNE D: Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? J. Clin. Oncol. (1992) 10:890-895.
   PubMed Web of Science ®Google Scholar
• MURRAY N: Treatment of small cell lung cancer: the state of the art. Lung Cancer (1997) 17(Suppl 1):S75-S89.
   PubMed Web of Science ®Google Scholar
• TURRISI AT, KIM K, BLUM R et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. (1999) 340:265-271.
   PubMed Web of Science ®Google Scholar
• TAMURA K, TAKADA M, KAWASE I et al.: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn. J. Cancer Res. (1997) 88(2):218-223.
   PubMedGoogle Scholar
• KASHII T, SAITO H, NEGORO S et al.: Phase II study of cisplatin plus etoposide with concurrent thoracic radiotherapy (TRT) followed by irintoecan plus cisplatin in limited stage small-cell lung cancer (SCLC); A West Japan Thoracic Oncology Group Trial. Lung Cancer (2005) 49(Suppl. 2):S322.
   Web of Science ®Google Scholar
• HAN JY, CHO KH, LEE DH et al.: Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J. Clin. Oncol. (2005) 23(15):3488-3494.
   PubMed Web of Science ®Google Scholar
• RAEFSKY EL, SPIGEL DR, GRECO FA et al.: Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2005) 23:633s.
   Web of Science ®Google Scholar
• SOHN J, MOON Y, LEE C et al.: Phase II trial of irinotecan and cisplatin with concurrent radiotherapy in limited-disease small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:662s.
   PubMed Web of Science ®Google Scholar
• LANGER C, SWANN S, WERNER-WASIK M et al.: Phase I study of combination irinotecan and cisplatin and either twice daily thoracic radiation (45Gy) or once daily thoracic radiotherapy (70Gy) in patients with limited small cell lung carcinoma (SCLC): Early toxicity analysis of RTOG 0241. Lung Cancer (2005) 49(Suppl. 2):S323.
   Web of Science ®Google Scholar
• MCLEOD HL, WATTERS JW: Irinotecan pharmacogenetics: is it time to intervene? J. Clin. Oncol. (2004) 22(8):1356-1359.
   PubMed Web of Science ®Google Scholar